Get it on Google Play

Enliven gets FDA alignment on Phase 3 CML trial design

October 6, 2026 4:05 PM EDT Send to a Friend
Enliven Therapeutics, Inc. (Nasdaq: ELVN) announced it has reached alignment with the U.S. Food and Drug Administration on the final ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login